Moreover, a lot of nicely founded adverse prognostic markers, which include U-CLL, ATM aberrations or NOTCH1/BIRC3 mutations, misplaced their detrimental impact in clients treated with VO. The one factor that remained predictive of a shorter development-no cost survival Within this cohort of suffere